Epidemiology Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Department of Epidemiology, University of Washington, Seattle, Washington.
Cancer Epidemiol Biomarkers Prev. 2023 Aug 1;32(8):1069-1078. doi: 10.1158/1055-9965.EPI-22-1291.
Among patients with cirrhosis, it remains unclear whether there are racial/ethnic differences in cirrhosis complications and mortality. We examined the associations between race/ethnicity and risk for hepatocellular carcinoma (HCC), cirrhosis decompensation, and all-cause mortality overall and by cirrhosis etiology.
US Veterans diagnosed with cirrhosis from 2001 to 2014 (n = 120,992), due to hepatitis C virus (HCV; n = 55,814), alcohol-associated liver disease (ALD; n = 36,323), hepatitis B virus (HBV; n = 1,972), nonalcoholic fatty liver disease (NAFLD; n = 17,789), or other (n = 9,094), were followed through 2020 for incident HCC (n = 10,242), cirrhosis decompensation (n = 27,887), and mortality (n = 81,441). Multivariable Cox proportional hazards regression was used to estimate adjusted hazard ratios (aHR) and 95% confidence intervals (CI).
Compared with non-Hispanic White patients, Hispanic patients had higher risk for HCC overall (aHR, 1.32; 95% CI, 1.24-1.41) and by cirrhosis etiology, particularly for ALD- (aHR, 1.63; 95% CI, 1.42-1.87) and NAFLD-cirrhosis (aHR, 1.76; 95% CI, 1.41-2.20), whereas non-Hispanic Black patients had lower HCC risk in ALD- (aHR, 0.79; 95% CI, 0.63-0.98) and NAFLD-cirrhosis (aHR, 0.54; 95% CI, 0.33-0.89). Asian patients had higher HCC risk (aHR, 1.70; 95% CI, 1.29-2.23), driven by HCV- and HBV-cirrhosis. Non-Hispanic Black patients had lower risk for cirrhosis decompensation overall (aHR, 0.71; 95% CI, 0.68-0.74) and by cirrhosis etiology. There was lower risk for mortality among all other racial/ethnic groups compared with non-Hispanic White patients.
Race/ethnicity is an important predictor for risk of developing HCC, decompensation, and mortality.
Future research should examine factors underlying these racial/ethnic differences to inform prevention, screening, and treatment for patients with cirrhosis.
在肝硬化患者中,肝硬化并发症和死亡率是否存在种族/民族差异仍不清楚。我们研究了种族/民族与肝细胞癌(HCC)、肝硬化失代偿和全因死亡率之间的关系,以及按肝硬化病因进行的分层分析。
我们对 2001 年至 2014 年间(n=120992)因丙型肝炎病毒(HCV;n=55814)、酒精性肝病(ALD;n=36323)、乙型肝炎病毒(HBV;n=1972)、非酒精性脂肪性肝病(NAFLD;n=17789)或其他原因(n=9094)导致肝硬化的美国退伍军人进行了研究,随访至 2020 年,以记录 HCC(n=10242)、肝硬化失代偿(n=27887)和死亡率(n=81441)的发生情况。采用多变量 Cox 比例风险回归模型估计调整后的风险比(aHR)和 95%置信区间(CI)。
与非西班牙裔白人患者相比,西班牙裔患者总体上 HCC 风险更高(aHR,1.32;95%CI,1.24-1.41),且按肝硬化病因分层后,西班牙裔患者 HCC 风险更高,尤其是 ALD(aHR,1.63;95%CI,1.42-1.87)和 NAFLD 肝硬化(aHR,1.76;95%CI,1.41-2.20),而非西班牙裔黑人患者的 HCC 风险较低,ALD(aHR,0.79;95%CI,0.63-0.98)和 NAFLD 肝硬化(aHR,0.54;95%CI,0.33-0.89)。亚洲患者 HCC 风险较高(aHR,1.70;95%CI,1.29-2.23),主要由 HCV 和 HBV 引起。非西班牙裔黑人患者的肝硬化失代偿总风险较低(aHR,0.71;95%CI,0.68-0.74),且按肝硬化病因分层后也是如此。与非西班牙裔白人患者相比,所有其他种族/民族群体的死亡率均较低。
种族/民族是发生 HCC、失代偿和死亡的重要预测因素。
未来的研究应探讨导致这些种族/民族差异的因素,为肝硬化患者的预防、筛查和治疗提供信息。